ABIVAX reports healthy volunteers Phase I data for ABX464

Paris, France, November 30th 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced positive results of first clinical evaluation of ABX464 in healthy volunteers for safety and pharmacokinetics. ABX464 is a once-daily orally available first-in-class small molecule drug candidate that inhibits HIV replication through an entirely new mechanism. A first Phase IIa clinical trial of ABX464 in naive patients infected with HIV was launched in 2015 with results expected in January 2016. A second Phase IIa in HIV patients already treated by standard therapy is planned to start in the near future.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41